These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 2390837)
1. Discriminant factors affecting early outcome of radioiodine treatment for Graves' disease. Kung AW; Choi P; Lam KS; Pun KK; Wang C; Yeung RT Clin Radiol; 1990 Jul; 42(1):52-4. PubMed ID: 2390837 [TBL] [Abstract][Full Text] [Related]
2. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Uy HL; Reasner CA; Samuels MH Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422 [TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy for Graves' disease: multivariate analysis of pretreatment parameters and early outcome. Turner J; Sadler W; Brownlie B; Rogers T Eur J Nucl Med; 1985; 11(6-7):191-3. PubMed ID: 3841065 [TBL] [Abstract][Full Text] [Related]
4. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis. Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550 [TBL] [Abstract][Full Text] [Related]
5. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414 [TBL] [Abstract][Full Text] [Related]
6. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. Catargi B; Leprat F; Guyot M; Valli N; Ducassou D; Tabarin A Eur J Endocrinol; 1999 Aug; 141(2):117-21. PubMed ID: 10427153 [TBL] [Abstract][Full Text] [Related]
7. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I. Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745 [TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554 [TBL] [Abstract][Full Text] [Related]
9. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440 [TBL] [Abstract][Full Text] [Related]
10. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism. El Refaei SM; Shawkat W Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187 [TBL] [Abstract][Full Text] [Related]
11. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism. Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167 [TBL] [Abstract][Full Text] [Related]
12. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034 [TBL] [Abstract][Full Text] [Related]
13. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration. Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085 [TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs. Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021 [TBL] [Abstract][Full Text] [Related]
15. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement]. Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826 [TBL] [Abstract][Full Text] [Related]
16. Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism. Horn-Lodewyk J Endocr J; 2019 Dec; 66(12):1047-1052. PubMed ID: 31391354 [TBL] [Abstract][Full Text] [Related]
17. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease. Van Isselt JW; de Klerk JM; Koppeschaar HP; Van Rijk PP Nucl Med Commun; 2000 Jul; 21(7):609-16. PubMed ID: 10994662 [TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography. Tsuruta M; Nagayama Y; Yokoyama N; Izumi M; Nagataki S Ann Nucl Med; 1993 Aug; 7(3):193-7. PubMed ID: 8217496 [TBL] [Abstract][Full Text] [Related]
20. Radioactive iodine in the treatment of Graves' disease. Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]